Saturday 17 October 2026
Export OVID’s income statement to Excel — free account
Ovid Therapeutics
OVID Healthcare Biotechnology
Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024. In the quarter to June 2026, revenue grew 463.9%, EPS fell 33.3%, free cash flow fell 268.5% and total debt fell 11.7%, each against the same quarter a year earlier.
2.15
0.11
−4.87%
Follow OVID
Ovid Therapeutics (OVID) P/E ratio
Ovid Therapeutics has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 3.0× (June 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 1.8× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.0×
Ten-year median
0.0×
Current reading's percentile
89
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OVID Ovid Therapeutics | n/m |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| OCS Oculis Holding AG compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | n/m |
| PROK ProKidney Corp. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)